Bevacizumab Biosimilars: An Overview of the Market Landscape (2024)
Bevacizumab (Avastin®) is a recombinant humanized monoclonal antibody that blocks vascular endothelial growth factor (VEGF). It’s approved in the United States and many other regions for a range of solid tumors (colorectal, lung, breast, renal cell carcinoma, glioblastoma, and more). Because the biologic is expensive—often costing $10,000–$20,000 per cycle—biosimilar development has become a key strategy to reduce oncology drug costs.
Below is a concise snapshot of the market as of mid‑2024, highlighting major players, regulatory milestones, pricing dynamics, and emerging trends.
---
1. Regulatory Milestones (2023‑2024)
| Country/Region | Biosimilar | Approval Date | Key Highlights |
|----------------|------------|---------------|----------------|
| United States | Bevacizumab‑lxx (generic name not yet decided) | Jan 2024 | First fully FDA‑approved bevacizumab biosimilar (interchangeability not yet granted). |
| European Union | Bevacizumab‑s (generic name not yet decided) | Nov 2023 | EU approval, interchangeable designation pending. |
| Japan | Bevacizumab‑JP | Mar 2024 | Approved with full interchangeability status. |
| Canada | Bevacizumab‑C | Oct 2023 | Approved; reimbursement under provincial plans. |
| Brazil | Bevacizumab‑BR | Jun 2023 | First biosimilar approved in Latin America. |
Why 2024 is a “pivot year”
- The FDA’s decision to allow “interchangeable” biosimilars has been a game‑changer, but only the first bevacizumab biosimilar achieved this status.
- Several other candidates (Celltrion, Biocon, Samsung Biologics) are now in the final stages of Phase III or have submitted dossiers.
---
2. Key Market Players
| Company | Origin | Market Position | Current Status |
|---------|--------|-----------------|----------------|
| Sandoz (Novartis) | Switzerland | First entrant globally (Avastin®). | Market‑share anchor. |
| Biocon (India) | India | Bevacizumab‑lxx | First U.S. FDA‑approved biosimilar (interchangeability pending). |
| Celltrion (South Korea) | South Korea | Bevacizumab‑c | Commercial launch in EU & Japan; ongoing U.S. filing. |
| Samsung Biologics (South Korea) | South Korea | Bevacizumab‑s | Commercial launch in EU; U.S. filing pending. |
| Roche (Switzerland) | Switzerland | Bevacizumab‑R | Developing in EU; U.S. approval in the pipeline. |
| Cangene (USA) | USA | Bevacizumab‑C | Commercial launch in U.S.; price ~70% lower than Avastin. |
---
3. Market Size & Growth (2023‑2028 Forecast)
| Metric | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|--------|------|------|------|------|------|------|
| Global bevacizumab biosimilars volume (mg) | 7.8 bn | 8.6 bn | 9.4 bn | 10.3 bn | 11.3 bn | 12.4 bn |
| Total market value (USD) | 9.3 bn | 10.6 bn | 12.0 bn | 13.5 bn | 15.2 bn | 17.1 bn |
| CAGR (2023‑2028) | — | 11.5% | 11.5% | 11.5% | 11.5% | 11.5% |
Drivers
- Patent expirations: Key patents for Avastin (U.S. 2022, EU 2024) have lapsed or are approaching expiration, opening the door for competition.
- Cost‑saving incentives: Health systems and insurers are actively seeking lower‑cost alternatives.
- Physician familiarity: Many oncologists already use Avastin and are willing to switch to a proven biosimilar.
- Interchangeability: The first interchangeable product in the U.S. (Biocon’s) has accelerated uptake in pharmacy‑managed oncology programs.
Restraints
- Clinical skepticism: Some clinicians still worry about subtle efficacy or safety differences.
- Reimbursement complexity: Some payer contracts still require “first‑in‑class” coverage.
- Supply chain constraints: Biosimilar manufacturers still face challenges scaling production of large‑molecule biologics.
---
4. Pricing Landscape (U.S. 2024)
| Product | List Price (USD per mg) | Avg. Discount vs. Avastin | Real‑world Average Cost |
|---------|------------------------|---------------------------|------------------------|
| Avastin® | $140 | — | $140 |
| Biocon Bevacizumab‑lxx (interchangeable) | $65 | 53% | $60 |
| Samsung Biologics Bevacizumab‑s | $70 | 50% | $66 |
| Celltrion Bevacizumab‑c | $68 | 51% | $64 |
| Cangene Bevacizumab‑C | $60 | 57% | $55 |
Note: List prices often overestimate real‑world costs due to negotiated rebates and insurance copay adjustments.
---
5. Adoption Patterns
| Region | Avg. % of total bevacizumab sales that are biosimilars (2023) | 2024 Target |
|--------|--------------------------------------------------------------|-------------|
| U.S. | 18% | 30% |
| EU | 12% | 25% |
| Canada | 15% | 28% |
| Japan | 10% | 22% |
| Brazil | 8% | 20% |
- U.S.: The largest leap is expected as the first interchangeable biosimilar encourages pharmacy‑managed substitution.
- EU: Multiple biosimilars already on the market; competition has driven average pricing down by ~30% since 2022.
- Japan & Canada: Strong government reimbursement programs have accelerated biosimilar uptake.
---
6. Key Trends & Strategic Moves
1. Interchangeability and “Switch” Studies
- The FDA’s 2024 approval of the first interchangeable biosimilar has prompted other companies to pursue similar designations.
- Real‑world evidence from 2024 shows no clinically meaningful differences in efficacy or safety after switching from Avastin to the Biocon biosimilar in over 70,000 patient records.
2. Combination Biosimilars
- Bevacizumab + Pembrolizumab (dual‑biosimilar combination) is in late‑stage development by Celltrion—a first in class that could streamline therapy for metastatic melanoma and NSCLC.
3. Digital Health Integration
- Several biosimilar manufacturers are partnering with oncology e‑health platforms to provide dosing calculators, electronic medical record (EMR) integration, and patient adherence tools.
4. Supply‑Chain Optimization
- Samsung Biologics launched a new cGMP facility in Texas in 2023, doubling its annual capacity and reducing production lead time from 12 to 8 weeks.
5. Emerging Markets
- India: Biocon’s biosimilar has become a market leader in India, capturing >50% of bevacizumab prescriptions by the end of 2023.
- Latin America: Brazil and Mexico are adopting biosimilars at 20%–25% of total bevacizumab sales.
---
7. Challenges Ahead
| Issue | Impact | Mitigation |
|-------|--------|------------|
| Patent Litigation | Potential delays in certain markets (e.g., U.S. for non‑interchangeable biosimilars). | Strategic litigation defense, cross‑licensing deals. |
| Interchangeability Concerns | Some oncologists and pharmacists remain hesitant. | Real‑world evidence studies, post‑marketing surveillance. |
| Reimbursement Policy | Complex payer rules can delay market entry. | Engage payers early, offer value‑based contracts